SGRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Surgery Partners Inc (SGRY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive indicators such as hedge fund buying and a slight pre-market price increase, the company's financial performance, recent analyst downgrades, and technical indicators suggest a cautious approach. The lack of strong proprietary trading signals further supports a hold recommendation.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 15.567), which could limit further upside in the short term.
The sector outlook for managed care is positive heading into 2026.
Analysts have consistently lowered price targets recently, citing payer mix pressures and lower earnings visibility. No significant insider or congress trading activity was observed, and there are no recent news catalysts.
In Q3 2025, revenue increased by 6.63% YoY to $821.5M, but net income dropped to -$22.7M (-28.39% YoY), and EPS fell to -0.18 (-28.00% YoY). Gross margin improved to 18.97% (+14.83% YoY), but overall profitability remains a concern.
Analysts have recently lowered price targets (e.g., Mizuho to $19, JPMorgan to $20, and Barclays to $18) while maintaining mixed ratings (Outperform, Neutral, Equal Weight). This reflects cautious optimism but highlights near-term challenges.
